Liquidia Corp. to Join S&P SmallCap 600 Index

By Chris Stiles • Tuesday, June 09 12:35 • Permanent Link

Liquidia Corp. said it will be added to the S&P SmallCap 600 index, effective before the opening of trading on June 22, 2026.

The company’s inclusion comes roughly 32 years after the benchmark was introduced in 1994. Liquidia, a Morrisville, N.C.-based biopharmaceutical company, will join an index made up of 600 U.S. small-cap companies selected on market capitalization, liquidity, shares available for public trading and profitability criteria.

Chief Executive Roger Jeffs said the move reflects the company’s execution and progress. The announcement did not include financial figures such as revenue, profit, or cash balances, but it did mark a notable change in Liquidia’s market profile: from not being part of the index to becoming one of its 600 constituents.

Liquidia develops therapies for respiratory and vascular diseases, including Yutrepia for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, along with L606 and generic treprostinil injection. The market has reacted to these announcements by moving the company's shares -0.38% to a price of $63.66. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.